Sarcoma, which occurs in young people and is a malignant tumor derived from mesenchymal tissue (including connective tissue and muscle). Sarcomas are highly malignant and develop rapidly! Common sarcomas include osteosarcoma, leiomyosarcoma, lymphosarcoma, and synovial sarcoma. Leiomyoma, lymphosarcoma, and synovial sarcoma may develop blood metastases at an early stage.
The preferred method of sarcoma is surgery. In order to seek a radical cure, domestic doctors usually require patients to have their limbs amputated. However, it is currently difficult to treat unresectable or advanced liposarcoma and leiomyosarcoma that occur behind the peritoneum and have large tumors. Hospitals at home and abroad tend to retain most of the limbs and then perform radiotherapy.
Sarcoma is not sensitive to chemotherapy drugs! The efficiency of local radiotherapy is also poor, but once the lung metastases are less effective.
Palbociclib capsule is a highly selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. It is also the first breast cancer immunotherapy inhibitor to be approved by the US FDA. Palbociclib capsules are targeted drugs for the treatment of sarcoma.
How Palbociclib works: All living cells undergo cell division, and Palbociclib can effectively inhibit the cell division process, and combining Palbociclib with other anti-cancer therapies such as endocrine therapy, chemotherapy, and other targeted therapies can treat many types of cancer Produce a powerful healing effect.
Targeted therapy can use a variety of drugs and other interventions to accurately identify and attack cancer cells without harming normal cells. Dr. Peter J. O’Dwyer said that in addition to neutrophils, Palbociclib has a The effect of cells is also small, and the drug can effectively inhibit the growth of tumors in tumors. As we discover new functions of target CDK4 / 6, we may develop new drug combinations as emerging anti-cancer agents.
According to the research results and early clinical trial results published by scientists at the University of Pennsylvania in the journal JAMA Oncology, the results of phase 2 clinical trials of 29 sarcoma patients show that the drug Palbociclib can achieve a median progression-free survival of 66% of patients 12 weeks. Palbociclib is effective in the treatment of sarcoma and can prolong the progression-free survival of patients.